17

Dec2021

PMPRB Proposed Amendments to the July 1, 2021 Guidelines

On October 28th, 2021, PMPRB provided their first update to the Notice & Comment that was issued on July 15, 2021. The primary takeaway is PMPRB will be providing patentees two reporting periods for compliance, a change from PMPRB's earlier position expecting one reporting period for ... Read More

17

Dec2021

Consultation Notice: Proposed Framework for a Potential Pan-Canadian Formulary

Consultation on the Proposed Framework for a Potential Pan-Canadian Formulary will be open for feedback from January 11 - February 25, 2022.  A discussion paper summarizing the Advisory Panel’s interim recommendations and proposed process will be posted on the CADTH website and CADTH will host an information session on January 18, 2022 at 1 p.m. (ET).  ... Read More

17

Dec2021

CADTH Pharmaceutical Reviews Update- Issue 27

On December 16, 2021, CADTH provided an update regarding CADTH’s drug review programs. A. Expanded Provisional Funding Algorithm Process CADTH has expanded the provisional funding algorithm process to include a new rapid algorithm process. This rapid algorithm process will be ... Read More

07

Dec2021

WHITEPAPER: Uncovering the Hidden Costs of Take-Home Cancer Drugs

In cancer care, patients often face increased anxiety and uncertainty about their future care pathway. This is paired with an immediate need for therapy to treat potentially aggressive disease. Coverage eligibility for THCD varies significantly across Canadian provinces, creating interprovincial differences. Gaps in coverage of THCDs across provinces lead to inequitable ... Read More

13

Sep2021

Welcome to the PDCI Team

PDCI Welcomes Véronique Scott & Ishan Kumar to the Team Ishan Kumar joins PDCI as Manager, Data Innovation and Insights. As a member of PDCI’s data insights team, Ishan’s role includes designing ... Read More

10

Aug2021

John Anacleto Joins PDCI as Director of Private Payer Strategies & Data Insights

John Anacleto Joins PDCI as Director of Private Payer Strategies & Data Insights Please join us in welcoming John to the PDCI Market Access Family! John joins ... Read More

03

Aug2021

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision with Significant Implications for the New PMPRB Guidelines In a unanimous July 29 decision, the Federal Court of Appeal (FCA) overturned a Federal Court judicial review and quashed the PMPRB decision in ... Read More

26

Jul2021

Deadline Extended: PMPRB Notice and Comment

Deadline Extended: PMPRB Notice and Comment - New Price Tests for Grandfathered Medicines On July 15th, 2021, the PMPRB invited stakeholders to comment on three amendments to the regulations with responses due by August 15th 2021. PMPRB announced today that the deadline has been ... Read More

29

Jun2021

Welcome Jessica Birrell and Rachel Arcand to the PDCI Team!

PDCI Market Access has further expanded its Market Access Team! Jessica joins PDCI as Manager, Market Access.  She will be responsible for coordinating our pricing and market access projects including HTA and payer ... Read More

06

May2021

PMPRB Announces the Guideline Monitoring and Evaluation Plan (GMEP) Consultation

The PMPRB is developing a Guideline Monitoring and Evaluation Plan (GMEP) that will analyze trends in the pharmaceutical market before and after the implementation of the new framework to assess whether it is working as intended, and to inform the need for any future adjustments. The PMPRB ... Read More